Literature DB >> 19903083

Lumenal part of the DC-LAMP protein is not required for induction of antigen-specific T cell responses by means of antigen-DC-LAMP messenger RNA-electroporated dendritic cells.

Brenda De Keersmaecker1, Carlo Heirman, Sabine Allard, Aude Bonehill, Jurgen Corthals, Kris Thielemans, Joeri L Aerts.   

Abstract

Previous studies showed that stimulation of T cells derived from HIV-1-infected patients with autologous dendritic cells electroporated with mRNA encoding HIV antigens can induce antigen-specific T cell responses in vitro. Linking the antigen to an MHC class II-targeting sequence, such as dendritic cell lysosome-associated membrane protein (DC-LAMP), in the mRNA construct results in presentation of antigenic peptides in both MHC class I and class II molecules and therefore enhances the induced T cell responses. To analyze whether the lumenal domain of DC-LAMP is required for optimal induction of cellular immunity against HIV antigens, we compared fusion constructs with or without the lumenal domain of the DC-LAMP protein. A human codon-optimized consensus Gag sequence and a chimeric cDNA sequence encompassing Tat, Rev, and Nef codons (TaReNef ) were cloned into a vector containing the DC-LAMP sequence with or without its lumenal domain. The Gag protein lacking the DC-LAMP-derived sequence altogether elicited only weak T cell responses. DCs electroporated with Gag or TaReNef linked to DC-LAMP were able to elicit similar levels of antigen-specific CD4(+) and CD8(+) T cell responses for both Gag and TaReNef, irrespective of the addition of the DC-LAMP lumenal domain. These data show that DC-LAMP-mediated antigen targeting is absolutely required for optimal T cell stimulation, but that in our experimental setup, the lumenal part of DC-LAMP does not improve the overall induction of antigen-specific T cell responses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19903083     DOI: 10.1089/hum.2009.080

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  3 in total

1.  Dendritic cell-based immunotherapy in ovarian cancer.

Authors:  An Coosemans; Ignace Vergote; Stefaan W Van Gool
Journal:  Oncoimmunology       Date:  2013-11-06       Impact factor: 8.110

2.  Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo.

Authors:  Daphné Benteyn; Sébastien Anguille; Sandra Van Lint; Carlo Heirman; An Mt Van Nuffel; Jurgen Corthals; Sebastian Ochsenreither; Wim Waelput; Katrien Van Beneden; Karine Breckpot; Viggo Van Tendeloo; Kris Thielemans; Aude Bonehill
Journal:  Mol Ther Nucleic Acids       Date:  2013-11-19       Impact factor: 10.183

3.  A synthetic DNA template for fast manufacturing of versatile single epitope mRNA.

Authors:  Wout de Mey; Phaedra De Schrijver; Dorien Autaers; Lena Pfitzer; Bruno Fant; Hanne Locy; Arthur Esprit; Lien Lybaert; Cedric Bogaert; Magali Verdonck; Kris Thielemans; Karine Breckpot; Lorenzo Franceschini
Journal:  Mol Ther Nucleic Acids       Date:  2022-08-17       Impact factor: 10.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.